Polish medicine stands at a critical turning point. On one side we hold substantial, if dispersed, potential — in 2024 more than 700,000 non-residents came to Poland for medical purposes.

 On the other, the absence of uniform standards and systemic fragmentation mean we are losing the contest for the premium patient to the Czech Republic and Türkiye. The key to unlocking the premium margin and exploiting the price arbitrage is the move from a phase of medical improvisation to a professional, certified ecosystem that will make Poland a central point on Europe’s medical map by 2027.

An end to medical improvisation — the Patient Coordination Centre (CKP)

The greatest barrier to growth in the Polish sector is the absence of operational continuity where the patient meets the system. The answer is the Patient Coordination Centre (CKP), which becomes the operational heart of the model. It introduces the “one coordinator” principle — a single point of contact for the patient, managing the entire value chain: from the clinical consilium, through the quality audit, to continuity of care in the patient’s home country.

Unlike organisations such as SPOIWO, which concentrate solely on primary care, the newly established Coordinated Care Employers’ Association (ZPOK) integrates the full chain: primary care — outpatient specialist care — hospital. That structure removes needless duplication of tests and builds the confidence of the foreign patient by offering a safe and predictable treatment pathway. As the programme’s organisational thesis puts it:

“The entire value chain is delivered by a single centre (the CKP), which removes fragmentation and allows full compliance with EU directives to be built into the model.”

Medical tourism versus cross-border medicine — the strategic “German hybrid”

Understanding the difference between medical tourism and cross-border medicine is fundamental to building profitability in a facility. The strategy for 2026–2027 draws a precise distinction between three dimensions of financing:

• Medical tourism: out-of-pocket services, paid directly by the patient or by private insurance (the dominant segment among patients from the United States, the United Kingdom and the Middle East).
• Cross-border medicine: reimbursement of costs by the insurance institution of the home country under Directive 2011/24/EU.
• Coordinated care: a systemic linking of the stages of treatment, securing continuity of information between the Polish clinic and the treating physician in the patient’s country of residence.

An exceptional opportunity for Polish operators lies in what may be called the German hybrid patient. Such a patient uses Directive 2011/24/EU to fund a standard procedure (an orthopaedic one, for instance) while paying out of pocket to upgrade to a premium standard. It is precisely this mechanism that allows Polish facilities to generate high margins while remaining attractively priced for the EU patient.

Trust Score and TQAMS — digital security as proof of quality

In highly specialised medicine, the patient is not buying a procedure but proof of safety. The new quality architecture rests on a Trust Score (0–100) in which Patient Safety & Cyber accounts for a full 20% of the weighting. In a digital age, proof of quality means conformity with NIS2 and systems such as WORM backup, which form a digital safety net for medical data.

The TQAMS standard (Transborder Quality Audit of Medical Services) was designed as an affordable bridge to global JCI accreditation. Implementing TQAMS costs between EUR 5,000 and 15,000, whereas obtaining JCI certification requires an outlay of USD 200,000 to 500,000. This allows Polish facilities to secure credible confirmation of cross-border standards quickly — a prerequisite for competing for patient volumes from the DACH and Scandinavian markets.

Eight routes to innovation — Poland’s unfair advantage in the EU

Poland is building its advantage over competitors in Türkiye and Albania by offering innovative therapies that are often not yet available elsewhere in the EU. Through a system of eight access routes, Polish centres can offer treatment under procedures such as RDTL (emergency access to drug technologies), compassionate use (early access programmes) and the therapeutic experiment under Article 21 of the Act on the medical professions.

The teplizumab case in Opole illustrates that advantage — an innovative therapy available in Poland despite its limited presence elsewhere in Europe. The participation of Polish facilities in the European Reference Networks (ERN) gives us unique clinical resources. It is precisely this access to pre-EU-approval therapies that constitutes our unfair advantage, positioning Poland as a proving ground for the most advanced medicine in the world.

The Israeli connector — a strategic alliance with Sheba Medical Center

The vision of Poland as a hub is completed by strategic cooperation with Sheba Medical Center, named by Newsweek among the best hospitals in the world in 2026. Under the memorandum of understanding signed, Polish clinics do not operate as a simple franchise but become authorised representatives of this global leader. That means a deep transfer of clinical and technological knowledge, not merely a marketing licence for a brand.

A central element of the alliance is interoperability and the planned integration of data with Poland’s P1 system. Polish physicians thereby gain a short cut to Sheba’s digital and oncological standards, allowing remote tumour boards and the secure transfer of medical records. The partnership is the catalyst that allows Polish facilities to implement processes unavailable to regional competitors.

Conclusion: are we ready for European mid-premium?

Poland has the opportunity to dominate the European mid-premium market, offering quality close to Swiss or German standards at a price 40–60% lower. Against a National Health Fund deficit forecast at 23 billion złoty for 2026, developing cross-border medicine ceases to be merely a business option — it becomes a national financial necessity, allowing the system to be supplied with private and EU transfer funding. This strategic window will close at the end of 2027. The question is whether Polish facilities will complete TQAMS certification and integrate into ZPOK structures in time to make full use of this historic moment. The answer will define the condition of Polish healthcare for the coming decade.